{"id":55815,"date":"2026-01-29T21:07:12","date_gmt":"2026-01-29T13:07:12","guid":{"rendered":"https:\/\/flcube.com\/?p=55815"},"modified":"2026-01-29T21:07:13","modified_gmt":"2026-01-29T13:07:13","slug":"wuxi-biologics-partners-with-sinorda-on-snd006-bispecific-antibody-for-autoimmune-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55815","title":{"rendered":"WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases"},"content":{"rendered":"\n<p><strong>WuXi Biologics<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2269:HKG\">HKG:\u202f2269<\/a>) announced a collaboration agreement with <strong>Guizhou Sinorda Biomedicineic Co., Ltd.<\/strong> to provide process development and manufacturing services for <strong>SND006<\/strong>, Sinorda\u2019s in\u2011house developed bispecific antibody targeting autoimmune diseases such as <strong>inflammatory bowel disease (IBD)<\/strong>. The partnership aims to advance preclinical pharmaceutical studies and clinical sample production, accelerating SND006\u2019s path to clinical application.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-structure-amp-strategic-terms\">Partnership Structure &amp; Strategic Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>WuXi Biologics (HKEX:\u202f2269) \/ Guizhou Sinorda Biotechnology<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>SND006 (innovative bispecific antibody)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Autoimmune diseases (IBD)<\/td><\/tr><tr><td><strong>WuXi\u2019s Role<\/strong><\/td><td>Process development, preclinical studies, clinical sample manufacturing<\/td><\/tr><tr><td><strong>Sinorda\u2019s Role<\/strong><\/td><td>In\u2011house drug developer; retains global rights<\/td><\/tr><tr><td><strong>Clinical Timeline<\/strong><\/td><td>Planned filings in China and US in 2026<\/td><\/tr><tr><td><strong>Future Scope<\/strong><\/td><td>Multi\u2011project collaboration from molecule discovery to clinical manufacturing<\/td><\/tr><tr><td><strong>Status<\/strong><\/td><td>In vitro functional validation completed<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-competitive-advantage\">Drug Profile &amp; Competitive Advantage<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Bispecific antibody designed to target key pathways in IBD pathogenesis<\/li>\n\n\n\n<li><strong>Market Need:<\/strong> IBD affects an estimated <strong>5\u202fmillion patients<\/strong> globally; China\u2019s IBD market growing at <strong>15% CAGR<\/strong> due to rising prevalence and biologics adoption<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> SND006 represents a <strong>next\u2011generation<\/strong> autoimmune therapy, potentially offering improved efficacy over current anti\u2011TNF\u03b1 standards<\/li>\n\n\n\n<li><strong>Manufacturing Edge:<\/strong> WuXi\u2019s <strong>large\u2011scale biologics capabilities<\/strong> enable rapid scale\u2011up and global supply chain readiness<\/li>\n\n\n\n<li><strong>Dual Filing Strategy:<\/strong> Concurrent China\/US clinical filings position SND006 for <strong>first\u2011in\u2011class<\/strong> bispecific IBD therapy<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China IBD Market:<\/strong> Valued at <strong>\u00a58\u202fbillion<\/strong> (~US$1.1\u202fbillion) in 2025, projected to reach <strong>\u00a515\u202fbillion<\/strong> by 2030<\/li>\n\n\n\n<li><strong>Global Bispecific Market:<\/strong> Expected to exceed <strong>$20\u202fbillion<\/strong> by 2030, driven by oncology and autoimmune applications<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts estimate <strong>\u00a52\u20133\u202fbillion<\/strong> (US$280\u2013420\u202fmillion) peak China sales for SND006 if approved<\/li>\n\n\n\n<li><strong>Strategic Validation:<\/strong> Partnership underscores WuXi\u2019s leadership in <strong>CDMO services<\/strong> for complex biologics while supporting Sinorda\u2019s innovative pipeline<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> IND\u2011enabling studies underway; clinical trial applications expected <strong>H2\u202f2026<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and revenue projections for SND006. Actual results may differ due to clinical trial outcomes, competitive dynamics, and regulatory review processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>WuXi Biologics (HKG:\u202f2269) announced a collaboration agreement with Guizhou Sinorda Biomedicineic Co., Ltd. to provide&#8230;<\/p>\n","protected":false},"author":1,"featured_media":55817,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[65,952,2629,292],"class_list":["post-55815","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-auto-immune","tag-hkg-2269","tag-sinorda-biomedicine","tag-wuxi-biologics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"WuXi Biologics (HKG:\u202f2269) announced a collaboration agreement with Guizhou Sinorda Biotechnology Co., Ltd. to provide process development and manufacturing services for SND006, Sinorda\u2019s in\u2011house developed bispecific antibody targeting autoimmune diseases such as inflammatory bowel disease (IBD). The partnership aims to advance preclinical pharmaceutical studies and clinical sample production, accelerating SND006\u2019s path to clinical application.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55815\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases\" \/>\n<meta property=\"og:description\" content=\"WuXi Biologics (HKG:\u202f2269) announced a collaboration agreement with Guizhou Sinorda Biotechnology Co., Ltd. to provide process development and manufacturing services for SND006, Sinorda\u2019s in\u2011house developed bispecific antibody targeting autoimmune diseases such as inflammatory bowel disease (IBD). The partnership aims to advance preclinical pharmaceutical studies and clinical sample production, accelerating SND006\u2019s path to clinical application.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55815\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-29T13:07:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-29T13:07:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2908.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55815#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55815\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases\",\"datePublished\":\"2026-01-29T13:07:12+00:00\",\"dateModified\":\"2026-01-29T13:07:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55815\"},\"wordCount\":345,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55815#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2908.webp\",\"keywords\":[\"Auto-immune\",\"HKG: 2269\",\"Sinorda Biomedicine\",\"WuXi Biologics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55815#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55815\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55815\",\"name\":\"WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55815#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55815#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2908.webp\",\"datePublished\":\"2026-01-29T13:07:12+00:00\",\"dateModified\":\"2026-01-29T13:07:13+00:00\",\"description\":\"WuXi Biologics (HKG:\u202f2269) announced a collaboration agreement with Guizhou Sinorda Biotechnology Co., Ltd. to provide process development and manufacturing services for SND006, Sinorda\u2019s in\u2011house developed bispecific antibody targeting autoimmune diseases such as inflammatory bowel disease (IBD). The partnership aims to advance preclinical pharmaceutical studies and clinical sample production, accelerating SND006\u2019s path to clinical application.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55815#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55815\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55815#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2908.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2908.webp\",\"width\":1080,\"height\":608,\"caption\":\"WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55815#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry","description":"WuXi Biologics (HKG:\u202f2269) announced a collaboration agreement with Guizhou Sinorda Biotechnology Co., Ltd. to provide process development and manufacturing services for SND006, Sinorda\u2019s in\u2011house developed bispecific antibody targeting autoimmune diseases such as inflammatory bowel disease (IBD). The partnership aims to advance preclinical pharmaceutical studies and clinical sample production, accelerating SND006\u2019s path to clinical application.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55815","og_locale":"en_US","og_type":"article","og_title":"WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases","og_description":"WuXi Biologics (HKG:\u202f2269) announced a collaboration agreement with Guizhou Sinorda Biotechnology Co., Ltd. to provide process development and manufacturing services for SND006, Sinorda\u2019s in\u2011house developed bispecific antibody targeting autoimmune diseases such as inflammatory bowel disease (IBD). The partnership aims to advance preclinical pharmaceutical studies and clinical sample production, accelerating SND006\u2019s path to clinical application.","og_url":"https:\/\/flcube.com\/?p=55815","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-29T13:07:12+00:00","article_modified_time":"2026-01-29T13:07:13+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2908.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55815#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55815"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases","datePublished":"2026-01-29T13:07:12+00:00","dateModified":"2026-01-29T13:07:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55815"},"wordCount":345,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=55815#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2908.webp","keywords":["Auto-immune","HKG: 2269","Sinorda Biomedicine","WuXi Biologics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55815#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55815","url":"https:\/\/flcube.com\/?p=55815","name":"WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=55815#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=55815#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2908.webp","datePublished":"2026-01-29T13:07:12+00:00","dateModified":"2026-01-29T13:07:13+00:00","description":"WuXi Biologics (HKG:\u202f2269) announced a collaboration agreement with Guizhou Sinorda Biotechnology Co., Ltd. to provide process development and manufacturing services for SND006, Sinorda\u2019s in\u2011house developed bispecific antibody targeting autoimmune diseases such as inflammatory bowel disease (IBD). The partnership aims to advance preclinical pharmaceutical studies and clinical sample production, accelerating SND006\u2019s path to clinical application.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55815#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55815"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=55815#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2908.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2908.webp","width":1080,"height":608,"caption":"WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55815#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"WuXi Biologics Partners with Sinorda on SND006 Bispecific Antibody for Autoimmune Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2908.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55815","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55815"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55815\/revisions"}],"predecessor-version":[{"id":55818,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55815\/revisions\/55818"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/55817"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55815"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55815"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55815"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}